{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:24:27Z","timestamp":1793042667036,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1136\/ijgc-2023-004872","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T12:50:17Z","timestamp":1705668617000},"page":"574-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients"],"prefix":"10.1016","volume":"34","author":[{"given":"Barnabe","family":"Bouvarel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Colomban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Sebastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7005-5785","authenticated-orcid":false,"given":"C\u00e9cile","family":"Loaec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Bourgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6167-5832","authenticated-orcid":false,"given":"Jean-Marc","family":"Classe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004872_bb0010","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2023-004872_bb0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.critrevonc.2019.08.002","article-title":"Hopes and failures in front-line ovarian cancer therapy","volume":"143","author":"Tsibulak","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/ijgc-2023-004872_bb0020","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline","volume":"34","author":"Wright","year":"2016","journal-title":"JCO"},{"key":"10.1136\/ijgc-2023-004872_bb0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ygyno.2019.02.019","article-title":"The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; a systematic review","volume":"153","author":"Timmermans","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004872_bb0030","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/IGC.0000000000001173","article-title":"Specific regions, rather than the entire peritoneal carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer","volume":"28","author":"Rosendahl","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004872_bb0035","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in Tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"JCO"},{"key":"10.1136\/ijgc-2023-004872_bb0040","article-title":"Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer","volume":"3","author":"van de Vrie","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2023-004872_bb0045","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/IGC.0000000000000368","article-title":"Predicting surgical outcome in patients with international federation of gynecology and obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models","volume":"25","author":"Rutten","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004872_bb0050","article-title":"Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian\/fallopian tube\/primary peritoneal cancer","volume":"10","author":"Roze","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2023-004872_bb0055","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004872_bb0060","doi-asserted-by":"crossref","first-page":"102294","DOI":"10.1016\/j.ctrv.2021.102294","article-title":"The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas","volume":"100","author":"You","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/ijgc-2023-004872_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2013.05.013","article-title":"The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)","volume":"130","author":"You","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004872_bb0070","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 elimination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004872_bb0075","article-title":"Benefit from fractionated dose-dense chemotherapy in patients with poor prognostic ovarian cancer: ICON-8 trial","volume":"7","author":"Colomban","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1136\/ijgc-2023-004872_bb0080","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s002800051093","article-title":"Successful management of microscopic residual disease in large bowel cancer","volume":"43 Suppl","author":"Sugarbaker","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/ijgc-2023-004872_bb0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004872_bb0090","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004872_bb0095","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004872_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1193","article-title":"Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: data from the GCIG meta-analysis group","volume":"32","author":"Corbaux","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004872_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2010.09.010","article-title":"Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment","volume":"120","author":"Aletti","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004872_bb0110","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/ijgc-2021-002951","article-title":"European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery","volume":"31","author":"Fotopoulou","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004872_bb0115","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ygyno.2020.09.004","article-title":"Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment","volume":"159","author":"Palmqvist","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004872_bb0120","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/IGC.0000000000001188","article-title":"When and who should perform epithelial ovarian cancer surgery","volume":"28","author":"Escayola","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004872_bb0125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-022-01732-7","article-title":"Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era","volume":"127","author":"You","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004872_bb0130","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/cncr.24317","article-title":"Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer","volume":"115","author":"Adams","year":"2009","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004872_bb0135","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann Surg Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:29:16Z","timestamp":1753234156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24013471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1048891X24013471"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004872","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}